In addition, Kamada et al. had suggested that QFT-Plus could be used as a potential tool for monitoring the efficacy of anti-TB therapy by showing a decline in the surrogate CD8+ T-cell response (difference “TB2 minus TB1”) at the end of treatment [24]. Here, CD8A is linked to tuberculosis.